7 months ago
Neuland Laboratories Reports Strong Q2FY26 Growth
Neuland Laboratories is a company that makes special ingredients for medicines.
They have two main parts: one that makes generic ingredients and another that helps other companies test and make their own medicines.
Recently, they had a great quarter with a lot of growth.
Their stock is a bit expensive, but it's because they're doing well in the part that makes more money.
They also have a new facility for making peptides, which are important for proteins.
The company has some debt, but not much, and they're expecting to keep growing.
Investors should watch how their orders and projects are doing because that can change quickly.
Neuland Laboratories reported 65% revenue and 195% PAT growth in Q2FY26.
The CMS division, which serves innovator companies, is the primary driver of revenue growth.
The company has negligible debt and expects sustained momentum in the CMS division.
EBITDA margins are tied to the proportion of revenues from the CMS division.
The stock trades at a premium valuation due to a CMS-heavy revenue mix.
- Who
- Neuland Laboratories
- What
- Reported strong Q2FY26 growth with 65% revenue and 195% PAT growth
- Where
- India
- When
- Q2FY26, with expectations for sustained momentum
- Why
- Due to strong performance in the CMS division and improved order-flow
Key facts
- Company
- Neuland Laboratories
- Revenue Growth (Q2FY26)
- 65%
- PAT Growth (Q2FY26)
- 195%
- Debt
- ₹6.6 crore (net)
- EBITDA Margins (Generics)
- 18-22%
- Stock Valuation
- 43 times one-year forward earnings
- Innovator Segment Revenue Contribution
- 93% of H1FY26 revenues
- Peptide Facility
- 2,000-litre large peptide facility expected by FY27




